Early  ||| S:0 E:6 ||| RB
neutral  ||| S:6 E:14 ||| JJ
prebiotic  ||| S:14 E:24 ||| JJ
oligosaccharide  ||| S:24 E:40 ||| JJ
supplementation  ||| S:40 E:56 ||| NN
reduces  ||| S:56 E:64 ||| VBZ
the  ||| S:64 E:68 ||| DT
incidence  ||| S:68 E:78 ||| NN
of  ||| S:78 E:81 ||| IN
some  ||| S:81 E:86 ||| DT
allergic  ||| S:86 E:95 ||| JJ
manifestations  ||| S:95 E:110 ||| NNS
in  ||| S:110 E:113 ||| IN
the  ||| S:113 E:117 ||| DT
first  ||| S:117 E:123 ||| JJ
5  ||| S:123 E:125 ||| CD
years  ||| S:125 E:131 ||| NNS
of  ||| S:131 E:134 ||| IN
life  ||| S:134 E:139 ||| NN
A  ||| S:139 E:141 ||| DT
mixture  ||| S:141 E:149 ||| NN
of  ||| S:149 E:152 ||| IN
neutral  ||| S:152 E:160 ||| JJ
prebiotic  ||| S:160 E:170 ||| JJ
oligosaccharides  ||| S:170 E:187 ||| NN
has  ||| S:187 E:191 ||| VBZ
been  ||| S:191 E:196 ||| VBN
shown  ||| S:196 E:202 ||| VBN
to  ||| S:202 E:205 ||| TO
reduce  ||| S:205 E:212 ||| VB
the  ||| S:212 E:216 ||| DT
incidence  ||| S:216 E:226 ||| NN
of  ||| S:226 E:229 ||| IN
atopic  ||| S:229 E:236 ||| JJ
dermatitis  ||| S:236 E:247 ||| NNS
( ||| S:247 E:248 ||| -LRB-
AD ||| S:248 E:250 ||| NNP
)  ||| S:250 E:252 ||| -RRB-
and  ||| S:252 E:256 ||| CC
allergy  ||| S:256 E:264 ||| NN
associated  ||| S:264 E:275 ||| VBN
symptoms  ||| S:275 E:284 ||| NNS
during  ||| S:284 E:291 ||| IN
the  ||| S:291 E:295 ||| DT
first  ||| S:295 E:301 ||| JJ
2  ||| S:301 E:303 ||| CD
years  ||| S:303 E:309 ||| NNS
of  ||| S:309 E:312 ||| IN
life ||| S:312 E:316 ||| NN
.  ||| S:316 E:318 ||| .
To  ||| S:318 E:321 ||| TO
evaluate  ||| S:321 E:330 ||| VB
if  ||| S:330 E:333 ||| IN
this  ||| S:333 E:338 ||| DT
protective  ||| S:338 E:349 ||| JJ
effect  ||| S:349 E:356 ||| NN
against  ||| S:356 E:364 ||| IN
allergy  ||| S:364 E:372 ||| NN
lasted  ||| S:372 E:379 ||| VBD
beyond  ||| S:379 E:386 ||| IN
the  ||| S:386 E:390 ||| DT
intervention  ||| S:390 E:403 ||| NN
period  ||| S:403 E:410 ||| NN
until  ||| S:410 E:416 ||| IN
5  ||| S:416 E:418 ||| CD
y  ||| S:418 E:420 ||| NN
of  ||| S:420 E:423 ||| IN
age ||| S:423 E:426 ||| NN
.  ||| S:426 E:428 ||| .
In  ||| S:428 E:431 ||| IN
a  ||| S:431 E:433 ||| DT
prospective ||| S:433 E:444 ||| JJ
,  ||| S:444 E:446 ||| ,
double  ||| S:446 E:453 ||| RB
blind ||| S:453 E:458 ||| JJ
,  ||| S:458 E:460 ||| ,
placebo-controlled  ||| S:460 E:479 ||| JJ
fashion ||| S:479 E:486 ||| NN
,  ||| S:486 E:488 ||| ,
healthy  ||| S:488 E:496 ||| JJ
term  ||| S:496 E:501 ||| NN
infants  ||| S:501 E:509 ||| NNS
at  ||| S:509 E:512 ||| IN
risk  ||| S:512 E:517 ||| NN
of  ||| S:517 E:520 ||| IN
atopy  ||| S:520 E:526 ||| NN
were  ||| S:526 E:531 ||| VBD
fed  ||| S:531 E:535 ||| VBN
either  ||| S:535 E:542 ||| RB
a  ||| S:542 E:544 ||| DT
prebiotic-supplemented  ||| S:544 E:567 ||| JJ
( ||| S:567 E:568 ||| -LRB-
0.8  ||| S:568 E:572 ||| CD
g ||| S:572 E:573 ||| CD
/ ||| S:573 E:574 ||| CD
100  ||| S:574 E:578 ||| CD
ml  ||| S:578 E:581 ||| CD
scGOS ||| S:581 E:586 ||| JJ
/ ||| S:586 E:587 ||| NNP
lcFOS ||| S:587 E:592 ||| NNP
)  ||| S:592 E:594 ||| -RRB-
or  ||| S:594 E:597 ||| CC
placebo-supplemented  ||| S:597 E:618 ||| NNP
( ||| S:618 E:619 ||| -LRB-
0.8  ||| S:619 E:623 ||| CD
g ||| S:623 E:624 ||| CD
/ ||| S:624 E:625 ||| CD
100  ||| S:625 E:629 ||| CD
ml  ||| S:629 E:632 ||| CD
maltodextrin ||| S:632 E:644 ||| CD
)  ||| S:644 E:646 ||| -RRB-
hypoallergenic  ||| S:646 E:661 ||| JJ
formula  ||| S:661 E:669 ||| NN
during  ||| S:669 E:676 ||| IN
the  ||| S:676 E:680 ||| DT
first  ||| S:680 E:686 ||| JJ
6  ||| S:686 E:688 ||| CD
mo  ||| S:688 E:691 ||| NN
of  ||| S:691 E:694 ||| IN
life ||| S:694 E:698 ||| NN
.  ||| S:698 E:700 ||| .
Following  ||| S:700 E:710 ||| VBG
this  ||| S:710 E:715 ||| DT
intervention  ||| S:715 E:728 ||| NN
period ||| S:728 E:734 ||| NN
,  ||| S:734 E:736 ||| ,
follow-up  ||| S:736 E:746 ||| NNP
continued  ||| S:746 E:756 ||| VBD
until  ||| S:756 E:762 ||| IN
5  ||| S:762 E:764 ||| CD
y  ||| S:764 E:766 ||| NN
of  ||| S:766 E:769 ||| IN
life ||| S:769 E:773 ||| NN
.  ||| S:773 E:775 ||| .
The  ||| S:775 E:779 ||| DT
present  ||| S:779 E:787 ||| JJ
study  ||| S:787 E:793 ||| NN
evaluated  ||| S:793 E:803 ||| NNS
( ||| S:803 E:804 ||| -LRB-
i ||| S:804 E:805 ||| FW
)  ||| S:805 E:807 ||| -RRB-
the  ||| S:807 E:811 ||| DT
cumulative  ||| S:811 E:822 ||| JJ
incidence  ||| S:822 E:832 ||| NN
of  ||| S:832 E:835 ||| IN
allergic  ||| S:835 E:844 ||| JJ
manifestations  ||| S:844 E:859 ||| NNS
during  ||| S:859 E:866 ||| IN
5  ||| S:866 E:868 ||| CD
y ||| S:868 E:869 ||| NN
,  ||| S:869 E:871 ||| ,
and  ||| S:871 E:875 ||| CC
( ||| S:875 E:876 ||| -LRB-
ii ||| S:876 E:878 ||| LS
)  ||| S:878 E:880 ||| -RRB-
the  ||| S:880 E:884 ||| DT
prevalence  ||| S:884 E:895 ||| NN
of  ||| S:895 E:898 ||| IN
allergic  ||| S:898 E:907 ||| NN
and  ||| S:907 E:911 ||| CC
persistent  ||| S:911 E:922 ||| JJ
allergic  ||| S:922 E:931 ||| JJ
manifestations  ||| S:931 E:946 ||| NNS
at  ||| S:946 E:949 ||| IN
5  ||| S:949 E:951 ||| CD
y ||| S:951 E:952 ||| NNS
.  ||| S:952 E:954 ||| .
Monitored  ||| S:954 E:964 ||| VBN
allergic  ||| S:964 E:973 ||| JJ
manifestations  ||| S:973 E:988 ||| NNS
were  ||| S:988 E:993 ||| VBD
AD ||| S:993 E:995 ||| NNP
,  ||| S:995 E:997 ||| ,
recurrent  ||| S:997 E:1007 ||| JJ
wheezing ||| S:1007 E:1015 ||| NN
,  ||| S:1015 E:1017 ||| ,
allergic  ||| S:1017 E:1026 ||| JJ
rhinoconjunctivitis  ||| S:1026 E:1046 ||| NN
and  ||| S:1046 E:1050 ||| CC
urticaria ||| S:1050 E:1059 ||| NN
.  ||| S:1059 E:1061 ||| .
Ninety-two  ||| S:1061 E:1072 ||| JJ
children  ||| S:1072 E:1081 ||| NNS
( ||| S:1081 E:1082 ||| -LRB-
50  ||| S:1082 E:1085 ||| CD
in  ||| S:1085 E:1088 ||| IN
placebo  ||| S:1088 E:1096 ||| JJ
group ||| S:1096 E:1101 ||| NN
,  ||| S:1101 E:1103 ||| ,
42  ||| S:1103 E:1106 ||| CD
in  ||| S:1106 E:1109 ||| IN
intervention  ||| S:1109 E:1122 ||| NN
group ||| S:1122 E:1127 ||| NN
)  ||| S:1127 E:1129 ||| -RRB-
completed  ||| S:1129 E:1139 ||| VBD
the  ||| S:1139 E:1143 ||| DT
5-y  ||| S:1143 E:1147 ||| NNP
follow-up ||| S:1147 E:1156 ||| NNP
.  ||| S:1156 E:1158 ||| .
The  ||| S:1158 E:1162 ||| DT
5-y  ||| S:1162 E:1166 ||| JJ
cumulative  ||| S:1166 E:1177 ||| JJ
incidences  ||| S:1177 E:1188 ||| NN
of  ||| S:1188 E:1191 ||| IN
any  ||| S:1191 E:1195 ||| DT
allergic  ||| S:1195 E:1204 ||| JJ
manifestation  ||| S:1204 E:1218 ||| NN
and  ||| S:1218 E:1222 ||| CC
atopic  ||| S:1222 E:1229 ||| JJ
dermatitis  ||| S:1229 E:1240 ||| NN
were  ||| S:1240 E:1245 ||| VBD
significantly  ||| S:1245 E:1259 ||| RB
lower  ||| S:1259 E:1265 ||| JJR
in  ||| S:1265 E:1268 ||| IN
the  ||| S:1268 E:1272 ||| DT
scGOS ||| S:1272 E:1277 ||| JJ
/ ||| S:1277 E:1278 ||| CD
lcFOS  ||| S:1278 E:1284 ||| JJ
group  ||| S:1284 E:1290 ||| NN
( ||| S:1290 E:1291 ||| -LRB-
30.9 ||| S:1291 E:1295 ||| CD
,  ||| S:1295 E:1297 ||| ,
19.1  ||| S:1297 E:1302 ||| CD
% ||| S:1302 E:1303 ||| NN
,  ||| S:1303 E:1305 ||| ,
respectively ||| S:1305 E:1317 ||| RB
)  ||| S:1317 E:1319 ||| -RRB-
compared  ||| S:1319 E:1328 ||| VBN
to  ||| S:1328 E:1331 ||| TO
placebo  ||| S:1331 E:1339 ||| VB
group  ||| S:1339 E:1345 ||| NN
( ||| S:1345 E:1346 ||| -LRB-
66 ||| S:1346 E:1348 ||| CD
,  ||| S:1348 E:1350 ||| ,
38  ||| S:1350 E:1353 ||| CD
% ||| S:1353 E:1354 ||| NN
,  ||| S:1354 E:1356 ||| ,
respectively ||| S:1356 E:1368 ||| RB
)  ||| S:1368 E:1370 ||| -RRB-
( ||| S:1370 E:1371 ||| -LRB-
p  ||| S:1371 E:1372 ||| CD
< ||| S:1372 E:1374 ||| SYM
0.01  ||| S:1374 E:1379 ||| CD
and  ||| S:1379 E:1382 ||| CC
< ||| S:1382 E:1384 ||| SYM
0.05 ||| S:1384 E:1388 ||| CD
) ||| S:1388 E:1389 ||| -RRB-
.  ||| S:1389 E:1391 ||| .
Children  ||| S:1391 E:1400 ||| NNS
in  ||| S:1400 E:1403 ||| IN
the  ||| S:1403 E:1407 ||| DT
scGOS ||| S:1407 E:1412 ||| JJ
/ ||| S:1412 E:1413 ||| CD
lcFOS  ||| S:1413 E:1419 ||| JJ
group  ||| S:1419 E:1425 ||| NN
tended  ||| S:1425 E:1432 ||| VBD
to  ||| S:1432 E:1435 ||| TO
have  ||| S:1435 E:1440 ||| VB
a  ||| S:1440 E:1442 ||| DT
lower  ||| S:1442 E:1448 ||| JJR
incidence  ||| S:1448 E:1458 ||| NN
of  ||| S:1458 E:1461 ||| IN
allergic  ||| S:1461 E:1470 ||| JJ
rhinoconjunctivitis ||| S:1470 E:1489 ||| NN
,  ||| S:1489 E:1491 ||| ,
and  ||| S:1491 E:1495 ||| CC
allergic  ||| S:1495 E:1504 ||| JJ
urticaria  ||| S:1504 E:1514 ||| NNS
( ||| S:1514 E:1515 ||| -LRB-
4.8  ||| S:1515 E:1519 ||| CD
vs  ||| S:1519 E:1522 ||| CD
16 ||| S:1522 E:1524 ||| CD
%  ||| S:1524 E:1526 ||| NN
for  ||| S:1526 E:1530 ||| IN
both  ||| S:1530 E:1535 ||| DT
manifestations ||| S:1535 E:1549 ||| NN
,  ||| S:1549 E:1551 ||| ,
p=0.08 ||| S:1551 E:1557 ||| CD
) ||| S:1557 E:1558 ||| -RRB-
.  ||| S:1558 E:1560 ||| .
There  ||| S:1560 E:1566 ||| EX
was  ||| S:1566 E:1570 ||| VBD
no  ||| S:1570 E:1573 ||| DT
difference  ||| S:1573 E:1584 ||| NN
in  ||| S:1584 E:1587 ||| IN
the  ||| S:1587 E:1591 ||| DT
cumulative  ||| S:1591 E:1602 ||| JJ
incidence  ||| S:1602 E:1612 ||| NN
of  ||| S:1612 E:1615 ||| IN
recurrent  ||| S:1615 E:1625 ||| JJ
wheezing ||| S:1625 E:1633 ||| NN
.  ||| S:1633 E:1635 ||| .
With  ||| S:1635 E:1640 ||| IN
regard  ||| S:1640 E:1647 ||| NN
to  ||| S:1647 E:1650 ||| TO
the  ||| S:1650 E:1654 ||| DT
prevalences  ||| S:1654 E:1666 ||| NN
at  ||| S:1666 E:1669 ||| IN
5  ||| S:1669 E:1671 ||| CD
y ||| S:1671 E:1672 ||| NN
,  ||| S:1672 E:1674 ||| ,
intervention  ||| S:1674 E:1687 ||| NN
group  ||| S:1687 E:1693 ||| NN
had  ||| S:1693 E:1697 ||| VBD
significantly  ||| S:1697 E:1711 ||| RB
lower  ||| S:1711 E:1717 ||| JJR
prevalence  ||| S:1717 E:1728 ||| NN
of  ||| S:1728 E:1731 ||| IN
any  ||| S:1731 E:1735 ||| DT
persistent  ||| S:1735 E:1746 ||| JJ
allergic  ||| S:1746 E:1755 ||| JJ
manifestation  ||| S:1755 E:1769 ||| NN
and  ||| S:1769 E:1773 ||| CC
rhinoconjunctivitis  ||| S:1773 E:1793 ||| NNS
( ||| S:1793 E:1794 ||| -LRB-
4.8 ||| S:1794 E:1797 ||| CD
,  ||| S:1797 E:1799 ||| ,
2.4  ||| S:1799 E:1803 ||| CD
% ||| S:1803 E:1804 ||| NN
,  ||| S:1804 E:1806 ||| ,
respectively ||| S:1806 E:1818 ||| RB
)  ||| S:1818 E:1820 ||| -RRB-
compared  ||| S:1820 E:1829 ||| VBN
to  ||| S:1829 E:1832 ||| TO
placebo  ||| S:1832 E:1840 ||| VB
( ||| S:1840 E:1841 ||| -LRB-
26 ||| S:1841 E:1843 ||| CD
,  ||| S:1843 E:1845 ||| ,
14  ||| S:1845 E:1848 ||| CD
% ||| S:1848 E:1849 ||| NN
,  ||| S:1849 E:1851 ||| ,
respectively ||| S:1851 E:1863 ||| RB
)  ||| S:1863 E:1865 ||| -RRB-
( ||| S:1865 E:1866 ||| -LRB-
p  ||| S:1866 E:1868 ||| CD
< ||| S:1868 E:1870 ||| SYM
0.01  ||| S:1870 E:1875 ||| CD
and  ||| S:1875 E:1879 ||| CC
=0.05 ||| S:1879 E:1884 ||| CD
) ||| S:1884 E:1885 ||| -RRB-
.  ||| S:1885 E:1887 ||| .
Prevalence  ||| S:1887 E:1898 ||| NNP
of  ||| S:1898 E:1901 ||| IN
persistent  ||| S:1901 E:1912 ||| JJ
AD  ||| S:1912 E:1915 ||| NNP
tended  ||| S:1915 E:1922 ||| VBD
to  ||| S:1922 E:1925 ||| TO
be  ||| S:1925 E:1928 ||| VB
lower  ||| S:1928 E:1934 ||| JJR
in  ||| S:1934 E:1937 ||| IN
the  ||| S:1937 E:1941 ||| DT
intervention  ||| S:1941 E:1954 ||| NN
group  ||| S:1954 E:1960 ||| NN
( ||| S:1960 E:1961 ||| -LRB-
2.4  ||| S:1961 E:1965 ||| CD
vs  ||| S:1965 E:1968 ||| CD
12 ||| S:1968 E:1970 ||| CD
% ||| S:1970 E:1971 ||| NN
,  ||| S:1971 E:1973 ||| ,
p=  ||| S:1973 E:1976 ||| CD
0.09 ||| S:1976 E:1980 ||| CD
) ||| S:1980 E:1981 ||| -RRB-
.  ||| S:1981 E:1983 ||| .
Although  ||| S:1983 E:1992 ||| IN
intervention  ||| S:1992 E:2005 ||| NN
group  ||| S:2005 E:2011 ||| NN
had  ||| S:2011 E:2015 ||| VBD
75 ||| S:2015 E:2017 ||| CD
%  ||| S:2017 E:2019 ||| NN
reduction  ||| S:2019 E:2029 ||| NN
in  ||| S:2029 E:2032 ||| IN
the  ||| S:2032 E:2036 ||| DT
prevalence  ||| S:2036 E:2047 ||| NN
of  ||| S:2047 E:2050 ||| IN
persistent  ||| S:2050 E:2061 ||| JJ
wheezing  ||| S:2061 E:2070 ||| NNS
( ||| S:2070 E:2071 ||| -LRB-
4.8  ||| S:2071 E:2075 ||| CD
vs  ||| S:2075 E:2078 ||| CD
14  ||| S:2078 E:2081 ||| CD
% ||| S:2081 E:2082 ||| NN
) ||| S:2082 E:2083 ||| -RRB-
,  ||| S:2083 E:2085 ||| ,
no  ||| S:2085 E:2088 ||| DT
significance  ||| S:2088 E:2101 ||| NN
was  ||| S:2101 E:2105 ||| VBD
shown ||| S:2105 E:2110 ||| VBN
.  ||| S:2110 E:2112 ||| .
Oligosaccharide  ||| S:2112 E:2128 ||| JJ
prebiotics  ||| S:2128 E:2139 ||| NNS
( ||| S:2139 E:2140 ||| -LRB-
scGOS ||| S:2140 E:2145 ||| NNP
/ ||| S:2145 E:2146 ||| NNP
lcFOS ||| S:2146 E:2151 ||| NNP
) ||| S:2151 E:2152 ||| -RRB-
,  ||| S:2152 E:2154 ||| ,
when  ||| S:2154 E:2159 ||| WRB
started  ||| S:2159 E:2167 ||| VBD
early  ||| S:2167 E:2173 ||| RB
in  ||| S:2173 E:2176 ||| IN
life  ||| S:2176 E:2181 ||| NN
have  ||| S:2181 E:2186 ||| VBP
a  ||| S:2186 E:2188 ||| DT
protective  ||| S:2188 E:2199 ||| JJ
effect  ||| S:2199 E:2206 ||| NN
against  ||| S:2206 E:2214 ||| IN
allergic  ||| S:2214 E:2223 ||| JJ
manifestations  ||| S:2223 E:2238 ||| NNS
in  ||| S:2238 E:2241 ||| IN
high  ||| S:2241 E:2246 ||| JJ
risk  ||| S:2246 E:2251 ||| NN
infants ||| S:2251 E:2258 ||| NNS
.  ||| S:2258 E:2260 ||| .
The  ||| S:2260 E:2264 ||| DT
protection  ||| S:2264 E:2275 ||| NN
lasts  ||| S:2275 E:2281 ||| VBZ
beyond  ||| S:2281 E:2288 ||| IN
infancy  ||| S:2288 E:2296 ||| NN
until  ||| S:2296 E:2302 ||| IN
5  ||| S:2302 E:2304 ||| CD
y  ||| S:2304 E:2306 ||| NN
of  ||| S:2306 E:2309 ||| IN
life ||| S:2309 E:2313 ||| NN
,  ||| S:2313 E:2315 ||| ,
for  ||| S:2315 E:2319 ||| IN
AD  ||| S:2319 E:2322 ||| NNP
and  ||| S:2322 E:2326 ||| CC
allergic  ||| S:2326 E:2335 ||| JJ
rhinoconjunctivitis ||| S:2335 E:2354 ||| NN
.  ||| S:2354 E:2356 ||| .
Long-term  ||| S:2356 E:2366 ||| JJ
follow-up  ||| S:2366 E:2376 ||| JJ
studies  ||| S:2376 E:2384 ||| NNS
in  ||| S:2384 E:2387 ||| IN
larger  ||| S:2387 E:2394 ||| JJR
populations  ||| S:2394 E:2406 ||| NNS
are  ||| S:2406 E:2410 ||| VBP
warranted  ||| S:2410 E:2420 ||| VBN
to  ||| S:2420 E:2423 ||| TO
evaluate  ||| S:2423 E:2432 ||| VB
the  ||| S:2432 E:2436 ||| DT
potential  ||| S:2436 E:2446 ||| JJ
preventive  ||| S:2446 E:2457 ||| JJ
effect  ||| S:2457 E:2464 ||| NN
of  ||| S:2464 E:2467 ||| IN
this  ||| S:2467 E:2472 ||| DT
mixture  ||| S:2472 E:2480 ||| NN
on  ||| S:2480 E:2483 ||| IN
asthma ||| S:2483 E:2489 ||| NN
.  ||| S:2489 E:2491 ||| .
